Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

LakeShore Biopharma Co., Ltd. (LSB) had Revenue of $80.82M for the most recently reported fiscal year, ending 2024-03-31.

Quarterly Annual

Figures for fiscal year ending 2024-03-31

Income Statement Financials
Revenue	$80.82M
Net Income	$-61.09M
Cost of Goods Sold	$16.59M
Gross Profit	$64.23M
Operating Expenses	$143.66M
Operating Income	$-62.84M
Non-Operating Income/Expense	$-1.32M
Pre-Tax Income	$-64.16M
Normalized Pre-Tax Income	$-64.16M
Income after Taxes	$-61.09M
Income from Continuous Operations	$-61.09M
Consolidated Net Income/Loss	$-61.09M
Normalized Income after Taxes	$-61.09M
EBIT	$-62.84M
EBITDA	$-56.89M
Weighted-Average Shares Outstanding (Basic)	10.69M
Weighted-Average Shares Outstanding (Diluted)	10.69M
Earnings per Share (EPS) (Basic)	$-5.70
Earnings per Share (EPS) (Diluted)	$-5.70
Balance Sheet Financials
Current Assets	$127.30M
Property, Plant, and Equipment	$66.72M
Long-Term Assets	$85.96M
Total Assets	$213.25M
Current Liabilities	$113.07M
Long-Term Debt	$13.95M
Long-Term Liabilities	$17.70M
Total Liabilities	$130.77M
Common Equity	$82.48M
Tangible Shareholders Equity	$72.44M
Shareholders Equity	$82.48M
Common Shares Outstanding	19.02M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-41.61M
Cash Flow from Investing Activities	$-6.24M
Cash Flow from Financial Activities	$28.93M
Beginning Cash	$52.20M
End Cash	$34.75M
Increase/Decrease in Cash	$-17.45M
Stock-Based Compensation	$1.38M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.13
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.14
Debt to Equity Ratio	0.71
Gross Margin	79.48%
Operating Margin	-77.75%
EBIT Margin	-77.75%
EBITDA Margin	-70.39%
Pre-Tax Profit Margin	-79.38%
Profit Margin	-75.59%
Free Cash Flow	$-47.85M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.38
Inventory Turnover	0.58
Receiveable Turnover	1.29
Days Sales in Receivables	282.72
Return on Equity	-74.07%
Return on Tangible Equity	-84.34%
Return on Assets	-28.65%
Return on Investments	-63.35%
Book Value Per Share	$4.34
Free Cash Flow per Share	$-4.47
Operating Cash Flow per Share	$-3.89

Data from Zacks Investment Research, Inc.